Proteomics profiling of a pre-metastatic colorectal cancer cohort identifies four proteomics-based subtypes and highlights ...

Neuroimmune modulation represents a promising treatment strategy that uses vagus nerve stimulation to reduce inflammation in ...

Janus kinase (JAK) inhibitors are associated with an increased risk for lung cancer but not overall cancer among older patients in the United States with rheumatoid arthritis (RA), according to study ...

Suggestions that rheumatoid arthritis (RA) patients suffer more cardiovascular events when treated with Janus kinase (JAK) inhibitors compared with tumor necrosis factor (TNF) blockers or other ...

In patients with RA, TNF inhibitor use during the 3 years after being diagnosed with early-stage lung, colorectal, or prostate cancer was not linked to decreased survival.

We’ll break down the TNF schedule available on leading sports betting apps, discuss the different types of bets NFL fans can make each week and then look at how bettors can maximize their sports ...

Ra is a Raft implementation by Team RabbitMQ. It is not tied to RabbitMQ and can be used in any Erlang or Elixir project. It is, however, heavily inspired by and geared towards RabbitMQ needs. Ra (by ...

According to Roto Grinders, expect fair weather at Soldier Field before and during the game. The temperature is expected to be around 44°F, with a 60% chance of precipitation and wind speeds of 8 ...

Efficacy and safety of deucravacitinib in patients with active psoriatic arthritis who are naïve to biologic disease-modifying antirheumatic drugs or have previously received TNF inhibitor ...

The presentation highlighted tolebrutinib’s potential as the first Bruton's tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the ...

Rheumatoid arthritis (RA) commonly causes joint pain, swelling, and inflammation. However, some people with RA will develop skin rashes. These can occur due to hives, vasculitis, and many other ...

The presentation highlighted tolebrutinib’s potential as the first Bruton’s tyrosine kinase (BTK) inhibitor to receive regulatory approval for the treatment of progressive MS. During the Clinical ...